Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FTX-101
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Find Therapeutics Receives FDA IND Clearance for FTX-101 in Chronic Optic Neuropathy
Details : FTX-101, is a first-in-class remyelinating agent that aims to restore vision in people suffering from Chronic Optic Neuropathy (CON), by modulating myelin blocking complex.
Product Name : FTX-101
Product Type : Peptide
Upfront Cash : Inapplicable
August 27, 2024
Lead Product(s) : FTX-101
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable